DRAXIMAGE DTPA (technetium tc-99m pentetate kit)
Draximage DTPA is a diagnostic radiopharmaceutical kit used to prepare Technetium Tc 99m pentetate. It is indicated for brain imaging in adults and for renal visualization, assessment of renal perfusion, and estimation of glomerular filtration rate (GFR) in both adult and pediatric patients. Additionally, when administered via inhalation, it is used for lung ventilation imaging and the evaluation of pulmonary embolism (when paired with perfusion imaging) in both adult and pediatric patients.
How DRAXIMAGE DTPA Works
Following intravenous administration, Technetium Tc 99m pentetate distributes within the vascular compartment and is cleared by the kidneys through glomerular filtration, which enables imaging of the renal system and assessment of filtration rates. When administered as an inhaled aerosol, the agent deposits on the epithelium of the ventilated pulmonary alveoli, allowing for the visualization of air distribution within the lungs.
Details
- Status
- Prescription
- First Approved
- 1989-12-29
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
DRAXIMAGE DTPA Approval History
What DRAXIMAGE DTPA Treats
1 indicationsDRAXIMAGE DTPA is approved for 1 conditions since its original approval in 1989. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Pulmonary Embolism
DRAXIMAGE DTPA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in DRAXIMAGE DTPA's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications DRAXIMAGE DTPA treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to DRAXIMAGE DTPA
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DRAXIMAGE DTPA FDA Label Details
Indications & Usage
FDA Label (PDF)DRAXIMAGE DTPA is indicated for the treatment of Pulmonary Embolism.
Track DRAXIMAGE DTPA with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.